Cancer patients with a rare post-transplant complication known as chronic graft versus host disease will benefit from a new NHS-funded medicine, Belumosudil (Rezurock ®). Stem cell or bone marrow transplant recipients facing this condition, affecting around 400 patients annually in England, experience immune system attacks on their organs. With current treatments often ineffective, around 200 severe cases will now receive Belumosudil over three years, following clinical endorsement. Administered orally, the drug inhibits proteins triggering inflammation, offering a breakthrough in managing symptoms and enhancing patients’ daily lives.
This milestone coincides with Rare Disease Day, underscoring the significance of innovative treatments for improving patient outcomes. NHS England’s Innovative Medicines Fund facilitates access to promising medications, including Belumosudil, exemplifying the healthcare system’s commitment to advancing patient care. Medical professionals and patient advocates alike hail the introduction of Belumosudil as a promising avenue for addressing the debilitating effects of chronic graft versus host disease and enhancing patient well-being post-transplant.
What impact do you think the availability of Belumosudil (Rezurock ®) will have on the quality of life for cancer patients experiencing chronic graft versus host disease post-stem cell or bone marrow transplant?